Pharming Group N.V.

Regulatory Filings • Apr 18, 2012

PHARMING LAUNCHES FREE INVESTOR RELATIONS APP

Leiden, The Netherlands, April 18, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM), announced the release today of its investor relations app for iPod, iPhone and iPad. The app is now available for free at the Apple App store at http://itunes.apple.com/us/app/pharming-ir/id515983241?ls=1&mt=8.

The Pharming investor relations app allows users to navigate the Company's investor relations materials as well as receive a stock quote and other important corporate information. Features in the app include the latest press releases and AFM filings as well as background information, videos and presentations from the Company.

"The launch of the Pharming investor relations app for iPod, iPhone and iPad provides our current and potential shareholders with immediate access to financial and corporate information regarding Pharming," commented Karl Keegan, Chief Financial Officer of Pharming. "Recognising the growing importance of mobile technology to all investors, Pharming launched this application to help ensure that our shareholders have instant access to our corporate and stock information. We are excited to be one of the early adopters of mobile technology that improves access to our shareholders information and creates broader awareness of the Pharming investment case."

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® (RHUCIN® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). RHUCIN® is partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is undergoing Phase III clinical development. The product is also being evaluated for follow-on indications in the areas of transplantation and reperfusion injury. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. A feasibility study, using the validated transgenic rabbit platform, aimed at the development of recombinant Factor VIII for the treatment of Haemophilia A is underway with partner, Renova Life, Inc. Additional information is available on the Pharming website, www.pharming.com. To download the Pharming Group Investor Relations App, click here.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact Karl Keegan, CFO: T: +31 (0)71 524 7400

FTI Consulting Julia Phillips/ John Dineen, T: +44 (0)207 269 7193

#